Chemed Corporation (CHE)
| Market Cap | 5.61B -29.9% |
| Revenue (ttm) | 2.54B +2.1% |
| Net Income | 259.78M -15.9% |
| EPS | 18.30 -10.8% |
| Shares Out | 13.22M |
| PE Ratio | 23.18 |
| Forward PE | 17.04 |
| Dividend | $2.40 (0.57%) |
| Ex-Dividend Date | Feb 23, 2026 |
| Volume | 152,412 |
| Open | 426.23 |
| Previous Close | 425.82 |
| Day's Range | 418.19 - 426.23 |
| 52-Week Range | 365.21 - 583.96 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 501.50 (+18.21%) |
| Earnings Date | Apr 23, 2026 |
About CHE
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides dire... [Read more]
Financial Performance
In 2025, Chemed's revenue was $2.53 billion, an increase of 4.06% compared to the previous year's $2.43 billion. Earnings were $265.24 million, a decrease of -12.17%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CHE stock is "Buy." The 12-month stock price target is $501.5, which is an increase of 18.21% from the latest price.
News
Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026
CINCINNATI, May 05, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2026 Health Care Conference on Tuesday,...
Chemed price target raised to $436 from $422 at RBC Capital
RBC Capital raised the firm’s price target on Chemed (CHE) to $436 from $422 and keeps a Sector Perform rating on the shares. Shares rallied over 10% on Friday following
Chemed Earnings Call Transcript: Q1 2026
VITAS delivered strong Q1 2026 results, raising full-year guidance for ADC, revenue, and EPS, while Roto-Rooter showed early signs of recovery despite higher marketing costs and weather disruptions. Franchise acquisitions and improved collections supported growth.
Chemed reports Q1 adjusted EPS $5.65, consensus $5.30
Reports Q1 revenue $657.5M, consensus $649.82M. As of March 31, Chemed (CHE) had total cash and cash equivalents of $16.9M and $91.2M in long-term debt.
Chemed raises FY26 adjusted EPS view to $24.00-$24.75 from $23.25-$24.25
Consensus $23.88. The company said, “Historically, we do not give quarterly updates to guidance. Due to the materially improved performance of VITAS, coupled with the level of share repurchases in
Chemed Reports First-Quarter 2026 Results
Full-Year Guidance Increased Due To: Strong VITAS Performance Re-purchase of 500,000 Shares in the Quarter Two Roto-Rooter Franchises Purchased for $20.6 Million CINCINNATI, April 23, 2026 (GLOBE NEWS...
This Newsletter Has a Multidecade Market-Beating Record. How It Finds Winning Stocks—and Dodges Losers.
Investment Quality Trends' yield-focused model portfolios have beaten the broad stock market since 1986.
Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement
CINCINNATI, April 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation ("Chemed") (NYSE:CHE) announced that it has entered into an Amended and Restated Credit Agreement for its Credit Facility (“Credit Agr...
Chemed To Report First Quarter 2026 Earnings April 23, Related Conference Call To Be Held On April 24
CINCINNATI, April 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2026, on Thursday, April 23, ...
Chemed’s Roto-Rooter purchases territory and assets of two franchises
Roto-Rooter Services Company, a wholly owned subsidiary of Chemed (CHE) Corporation, announced it has purchased the territory and assets of the franchises operating in San Francisco, California and Fo...
Roto-Rooter Completes Acquisitions for Two Significant Territories
Two acquisitions completed by Roto-Rooter Services Company for combined $20.6 million in Fort Worth, Texas and San Francisco, California on March 31, 2026.
Oppenheimer explores Chemed value in possible Roto-Rooter split
Oppenheimer still believes Chemed (CHE) can unlock Roto-Rooter’s value operationally. However, it makes sense to looking at the value of the two companies separately given their lack of synergies and
Chemed Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Management expressed confidence in VITAS's growth and margin outlook, driven by strong Florida performance and new market entries, while Roto-Rooter guidance remains conservative amid ongoing marketing and collection challenges. Strategic alternatives for Roto-Rooter will be considered if recovery stalls in 2026.
Chemed Corporation to Present at the Oppenheimer 36th Annual Healthcare Conference
CINCINNATI, March 12, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 36th Annual Healthcare Conference on Thursda...
Chemed price target lowered to $500 from $580 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn lowered the firm’s price target on Chemed (CHE) to $500 from $580 and keeps an Outperform rating on the shares. The firm notes Chemed reported a
Chemed downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Chemed (CHE) to Sector Perform from Outperform with a price target of $422, down from $572. The firm cites near and longer-term Roto-Rooter margin uncertainty for the
Chemed Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Chemed Corporation (NYSE: CHE). The investigation focuses on Chemed's exec...
Chemed downgraded to Neutral from Buy at BofA
BofA analyst Joanna Gajuk downgraded Chemed (CHE) to Neutral from Buy with a price target of $450, down from $595.
Chemed downgraded at BofA with issues at Roto ‘not easing up’
BofA downgraded Chemed (CHE) to Neutral from Buy with a price target of $450, down from $595. Q4 EBITDA missed expectations and 2026 EBITDA guidance is 6% below expectations on
Chemed price target lowered to $400 from $475 at Jefferies
Jefferies lowered the firm’s price target on Chemed (CHE) to $400 from $475 and keeps a Hold rating on the shares. Q4 results were “disappointing” and revenue guidance ranges for
Chemed Earnings Call Transcript: Q4 2025
Fourth quarter 2025 results missed expectations due to margin pressure at both subsidiaries, but operational changes and market adjustments are expected to drive improved revenue and profitability in 2026, especially in the second half. VITAS and Roto-Rooter both face transitional challenges but maintain a positive long-term outlook.
Chemed reports Q4 adjusted EPS $6.42, consensus $7.03
Reports Q4 revenue $639.3M, consensus $659.09M.
Chemed sees FY26 EPS $23.25-$24.25, consensus $25.41
VITAS 2026 revenue, prior to Medicare Cap, is estimated to increase 5.5% to 6.5% when compared to 2025. ADC is estimated to increase 3.5% to 4.0%. Full year EBITDA margin,
Chemed Reports Fourth-Quarter 2025 Results
CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest providers of end-of-life care, and Roto...
Chemed board authorizes additional $300M for stock repurchases
Chemed (CHE) Corporation announced that the Board of Directors has formally authorized an additional $300M for stock repurchases under Chemed’s existing share repurchase program. These share repurchas...